Keywords: Eli Lilly, Financial results, Third-quarter 2012

Eli Lilly 3rd-qtr 2012 sales fall on Zyprexa generic competition

Article | 25 October 2012

US pharma major Eli Lilly (NYSE: LLY) yesterday reported third-quarter 2012 financial results, showing that worldwide revenue declined 11% to $5.44 billion, driven ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Eli Lilly

Go to company listing